Monoclonal antibody drugs continue to prevail in the clinical pipeline for their efficacy, safety and versatility in providing solutions to a broad range of diseases. Following this trend, antibody drug discovery (ADD) workflows are evolving to expedite lead identification through single B Cell technologies.
GenScript’s new white paper provides an overview of the evolving ADD platforms, illustrating how new single B Cell strategies and advanced antibody generation platforms can accelerate and expand access to valuable leads.
